Pacira BioSciences
PCRX
132 hedge funds and large institutions have $2.02B invested in Pacira BioSciences in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 49 increasing their positions, 52 reducing their positions, and 18 closing their positions.
100% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $6.17M
18% more capital invested
Capital invested by funds: $1.7B → $2.02B (+$314M)
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
2% more funds holding
Funds holding: 130 → 132 (+2)
6% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 52
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Daruma Capital Management
New York
|
+$46M |
| 2 |
Bank of New York Mellon
New York
|
+$33.1M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$27.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.5M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$22.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$38.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$24.4M |
| 3 |
Calamos Advisors
Naperville,
Illinois
|
-$22.9M |
| 4 |
CCM
Century Capital Management
Boston,
Massachusetts
|
-$19M |
| 5 |
Millennium Management
New York
|
-$17M |
PCRX Hedge Fund Activity: Q4 2013 in Review
132 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2013, worth a combined $2.02B — up 18% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PCRX positions and 18 closed out — a net gain of 2 holders — while 49 added to existing stakes and 52 trimmed.
The largest buyer was Daruma Capital Management, adding an estimated $46M. The largest seller was MPM Asset Management, cutting an estimated $38.1M.
- 132 institutional investors held Pacira BioSciences (PCRX) as of Q4 2013, up from 130 in Q3 2013.
- Funds reported $2.02B of Pacira BioSciences stock for Q4 2013, up 18% quarter-over-quarter.
- 20 funds opened new Pacira BioSciences positions in Q4 2013 and 18 closed out, a net change of +2 holders.
- The largest Pacira BioSciences buyer in Q4 2013 was Daruma Capital Management, an estimated $46M added.
- The largest Pacira BioSciences seller in Q4 2013 was MPM Asset Management, an estimated $38.1M sold.
Based on aggregated 13F filings for Q4 2013.